The founders of the Polish company Diagendo have developed a test to diagnose endometriosis. The EndoRNA test has a real chance to revolutionise diagnosis and open the way for millions of women to effectively fight this mysterious disease.

Endometriosis is insidious, painful, psychologically debilitating, mysterious and therefore often underestimated by doctors. According to the WHO, it affects up to 190 million girls and women of reproductive age. It is estimated to account for up to half of all cases of female infertility. And it takes as long as 5-6 years from the appearance of the first symptoms to the diagnosis of the disease.

“Endometriosis is my biggest professional hobby. I have authored or co-authored almost 20 publications on it in leading scientific journals. After years of studying this issue, and with a bit of luck, I managed to discover a biomarker of this disease, which is at the basis of our test”, says Professor Jacek Malejczyk, one of the founders of Diagendo.

The EndoRNA test has a real chance to revolutionise the diagnosis of endometriosis. Until now, it has been based on a not very effective medical history, a hard-to-access imaging method or an invasive laparoscopic procedure.

The method of the Diagendo creators detects the disease through a biopsy from the endometrium during a routine visit to the gynaecologist and examination of the sample in the laboratory. The researchers managed to achieve a 94 % diagnostic sensitivity and a 93.9 % predictive value.

Diagendo’s founders patented the test, build a manufacturing pathway for it, and obtain approval to market it as a medical device. Now they want to commercialise their discovery. In Poland, they are focusing on creating partnerships with diagnostic networks, gynaecology clinics and hospitals, as well as medical device distributors. Outside Poland, they are looking for distribution partners among global pharmaceutical companies.

Arkadiusz Słomczyński